← Back to Search

Cannabinoid

CanniMed™ DPF-III Volcano® Vapourization for Osteoarthritis (CAPRI Trial)

Phase 2
Waitlist Available
Led By Mark Ware, MD
Research Sponsored by Prairie Plant Systems Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes post-dose
Awards & highlights

CAPRI Trial Summary

Primary Objective: - To determine the analgesic dose-response characteristics of vapourized cannabinoids with varying degrees of delta-9-tetrahydrocannabiol (THC)/ Cannabidiol (CBD) ratios. Secondary Objectives: To compare functional changes and patient preferences of different cannabinoid (THC, CBD) profiles in patients with OA (Osteoarthritis); To describe the Pharmacokinetics (PK) of vapourized cannabis of differing cannabinoid profiles in patients with OA; To explore the short term safety of vapourized cannabis with different cannabinoid profiles. To describe the incidence and severity of psychoactive events.

Eligible Conditions
  • Osteoarthritis

CAPRI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 15, 30, 45, 60, 90, 120, 150, 180 minutes post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total pain reduction of vapourized cannabinoids with varying degrees of THC/CBD ratios in patients with painful OA of the knee.
Secondary outcome measures
Blood chemistry - liver function
Blood chemistry - renal function
Cannabinoid urine analysis at screening and for washout confirmation
+8 more

CAPRI Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: CanniMed™ DPF-V Volcano® VapourizationExperimental Treatment2 Interventions
Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
Group II: CanniMed™ DPF-IV Volcano® VapourizationExperimental Treatment2 Interventions
Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
Group III: CanniMed™ DPF-III Volcano® VapourizationExperimental Treatment2 Interventions
Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
Group IV: CanniMed™ DPF-II Volcano® VapourizationExperimental Treatment2 Interventions
Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
Group V: CanniMed™ DPF-I Volcano® VapourizationExperimental Treatment2 Interventions
Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
Group VI: CanniMed™ DPF-P Volcano® VapourizationPlacebo Group2 Interventions
Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for "industrial hemp", as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Medical Cannabis
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Prairie Plant Systems Inc.Lead Sponsor
Research Institute of the McGill University Health CenterUNKNOWN
2 Previous Clinical Trials
4,975 Total Patients Enrolled
McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
442 Previous Clinical Trials
159,134 Total Patients Enrolled
3 Trials studying Osteoarthritis
88 Patients Enrolled for Osteoarthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee
2015. "Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02324777.
All > Arthritis > Oa
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top